Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Pfizer’s big antibiotic buyout: a sign of things to come?

Pfizer’s acquisition of AstraZeneca’s antibiotics unit will certainly strengthen its anti-infectives portfolio, but is it also a precursor to bigger moves from the US drug maker? Elly Earls reports.

Go Top